CPS Technologies (NASDAQ:CPSH) reported $6.70 million in sales this quarter. This is a 21.49 percent increase over sales of $5.51 million the same period last year.
Vivos Therapeutics Stock Is Moving Higher On FDA Approval For Its Sleep Apnea Device
The FDA has granted 510(k) clearance to Vivos Therapeutics Inc’s (NASDAQ:VVOS) mmRNA (modified mandibular Repositioning Nighttime Appliance) obstructive sleep apnea (OSA) device.…